Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia

Cancer Invest. 2006 Oct;24(6):562-6. doi: 10.1080/07357900600894757.

Abstract

Absorption of a physiological dose of ferrous iron was studied in 18 patients with solid malignancy receiving epoetin therapy for mild chemotherapy-associated anemia. The historical control group consisted of 25 iron replete volunteers (iron absorption 20 +/- 11% in males and 26 +/- 13% in females) and 21 patients with uncomplicated iron deficiency (iron absorption 71 +/- 19%). Iron absorption was increased in the majority of the cancer patients (iron absorption 59 +/- 35%). There were no significant differences in iron absorption between cancer patients who were iron replete or iron deficient according to current clinical practice guidelines (iron deficiency: transferrin saturation < 20% and/or serum ferritin < 100 ng/mL). Red cell iron incorporation was not disturbed in the majority (89%) of patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anemia / chemically induced
  • Anemia / drug therapy*
  • Anemia / metabolism
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Epoetin Alfa
  • Erythropoietin / therapeutic use*
  • Female
  • Hematinics / therapeutic use*
  • Hemoglobins / metabolism
  • Humans
  • Intestinal Absorption*
  • Iron / metabolism*
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Organoplatinum Compounds / administration & dosage
  • Recombinant Proteins

Substances

  • Hematinics
  • Hemoglobins
  • Organoplatinum Compounds
  • Recombinant Proteins
  • Erythropoietin
  • Epoetin Alfa
  • Iron